Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berzosertib + topotecan in platinum-resistant relapsed SCLC
CTR20211414Phase 2Terminated
- Sponsor
- Merck KGaA
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of berzosertib in small cell lung cancer (SCLC), sponsored by Merck KGaA. Started Jun 2021; status: terminated.
02
Drugs
berzosertib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20211414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211414.